New Federal Scrutiny of DTC Drug Ads

New Federal Scrutiny of DTC Drug Ads:
What It Means for Our Partners

Enforcement
Pulse

US regulators are tightening oversight of drug promotion across television, websites, and social media. The immediate focus is enforcement under existing fair-balance and non-misleading standards. The FDA said it is issuing roughly 100 cease & desist letters & thousands of Warning and Untitled Letters to sponsors and partners and will monitor corrective actions.

The scale and opacity of this push (many letters at once with limited public details) has put industry in holding pattern while clarity around corrective actions comes into focus. This is unprecedented for an industry built on guidelines, protocols and regulations and will drive caution in the short-term as more details emerge.

FDA Enforcement Index

First Wave of FDA Untitled Letters, Most Often Triggered by Overstated Efficacy Claims

Note: Some FDA Untitled Letters contained multiple offenses and are therefore counted more than once according to the nature of each offense.

U.S. Food and Drug Administration. Untitled Letters. Published September 25, 2025. Accessed September 25, 2025. FDA Website

FDA Untitled Letters by Nature of Offense
Updated 9/25/25

Tap each bar to
see offense type

*This data set is based on the initial 53 Untitled Letters published by the FDA. Some FDA Untitled Letters contained multiple offenses and are therefore counted more than once according to the nature of each offense.

Note: Some FDA Untitled Letters contained multiple offenses and are therefore counted more than once according to the nature of each offense.

U.S. Food and Drug Administration. Untitled Letters. Published September 25, 2025. Accessed September 25, 2025. FDA Website

PHC continuously monitors FDA enforcement and apply a proprietary, data-backed scoring rubric to evaluate this barrage of information, in the FDA ENFORCEMENT index.

Leaning on this expertise, we uncover trends and provide insight into the meaning for brands as well as brand risk and opportunities. What's the risk to your brand?

To see the full list of the individual letters, please visit the FDA website directly

Note: Some FDA Untitled Letters contained multiple offenses and are therefore counted more than once according to the nature of each offense.

U.S. Food and Drug Administration. Untitled Letters. Published September 25, 2025. Accessed September 25, 2025. FDA Website